Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=33 Supportive Care

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

Bile Duct Disorder · Endocrine Pancreas Disorder

Bottom Line

View on ClinicalTrials.gov: NCT03775681 ↗
Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: The Number of Participants With Overall Success of ERCP With LMA Gastro — 28 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Endoscopic Retrograde Cholangiopancreatography (Procedure); Interview (Other); Laryngeal Mask Airway (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
M.D. Anderson Cancer Center
Primary completion
Apr 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
The Number of Participants With Overall Success of ERCP With LMA Gastro		 28 —

Summary

This trial determines the feasibility of Laryngeal Mask Airway Gastro (Laryngeal Mask Airway) when used on patients who are undergoing endoscopic retrograde cholangiopancreatography for pancreas and bile duct disorders. Laryngeal Mask Airway is a device that helps patients breathe while they are asleep during procedures.

Eligibility Criteria

Inclusion Criteria

  • Adult patients undergoing elective ERCP with general anesthesia

Exclusion Criteria

  • Patients with propofol allergy
  • Patients at increased aspiration risk
  • Patients with abnormal head/neck pathology preventing LMA Gastro placement
  • Patients with surgical or radiation treatment to the head/neck making LMA Gastro placement difficult
  • Esophagectomy patients
  • Patients already intubated upon arrival to endoscopy suite
  • Patients undergoing endoscopic ultrasound (EUS)
  • Patients with body mass index (BMI) 35 kg/m^2
  • Non-English speaking patients
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03775681). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search